Genedrive Share News (GDR)

Genedrive enters clinical trial deal in US for MT-RNR1 US approval

(Alliance News) - Genedrive PLC on Wednesday said it has entered into a clinical trial agreement to support clinical studies to progress the regulatory approval of its MT-RNR1 product.

LONDON MARKET CLOSE: FTSE 100 up thanks to US economic data

(Alliance News) - Stock prices in London closed mostly higher on Wednesday, after some data from the US reinforced the interest rate cut trajectory across the Atlantic.

Genedrive shares jump on NICE test recommendation

(Sharecast News) - Genedrive shares were surging on Wednesday, after it received a significant endorsement from the UK's National Institute for Health and Care Excellence (NICE) regarding its 'CYP2C19-ID' test.

Genedrive shares surge as UK's NICE backs test for ischaemic stroke

(Alliance News) - Genedrive PLC on Wednesday praised the National Health Service's work on strokes and mini strokes as a test by the company received a recommendation from the UK's National Institute for Health & Care Excellence.

AIM WINNERS & LOSERS: UK NICE backs Genedrive test; Corero renews deal

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

EARNINGS AND TRADING: 888 advances US exit; Arrow ups reserve estimate

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Genedrive receives R&D tax credit, plans fundraise

(Sharecast News) - Point-of-care pharmacogenetic testing company Genedrive announced the receipt of a research and development tax credit totalling £0.8m on Friday, taking its unaudited cash balances to £1.2m.

Genedrive down as plans equity raise despite GBP800,000 tax credit

(Alliance News) - Genedrive PLC shares fell on Friday, after it said it has received a GBP800,000 research and development tax credit.

TRADING UPDATES: Coro seals sale terms, Powerhouse makes good progress

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Genedrive set to apply for NICE EVA funding

(Sharecast News) - Genedrive shares rose on Monday, on the launch of the NICE early value assessment (EVA) evidence generation funding call, backed by the National Institute for Health and Care Research (NIHR).

LONDON BRIEFING: MoneySupermarket credits Insurance for growth in 2023

(Alliance News) - Stocks in London are set to fall at Monday's open, as concerns over US inflation trends curb risk appetite, and damp hopes of interest rate cuts from the Federal Reserve.

Genedrive confirms £0.6m equity prepayment drawdown

(Sharecast News) - Genedrive confirmed a planned £0.6m drawdown as part of its £5m equity prepayment facility on Tuesday, which it initially disclosed on 31 March 2023.

IN BRIEF: Genedrive draws down GBP600,000 on prepayment facility

Genedrive PLC - Manchester, England-based molecular diagnostics company - Draws down GBP600,000 on its GBP5 million equity prepayment facility. In March last year, Genedrive agreed the GBP5 million equity prepayment facility with Riverfort Global Opportunities PCC Ltd. At the time it said that proceeds would be used towards the commercialisation of the antibiotic-induced hearing loss test, Genedrive MT-RNR1 ID Kit, and enhancing the Genedrive platform as well as providing additional working capital.

UK shareholder meetings calendar - next 7 days

Genedrive gets first product orders from several countries

(Sharecast News) - Point-of-care pharmacogenetic testing company Genedrive has received its first orders for Genedrive MT-RNR1 products from several countries, it announced on Wednesday, including France, Austria, Greece, Saudi Arabia, Turkey, and the Netherlands.